Lapatinib治疗乳腺癌的研究进展
China Cancer(2009)
Abstract
Lapatinib(拉帕替尼)是一种新型的口服双重酪氨酸激酶抑制剂(TKI),它能同时抑制表皮生长因子受体(EGFR)和表皮生长因子受体-2(HER-2)的酪氨酸激酶活性.Lapatinib的临床前期及临床研究结果表明:lapatinib在体外与活体试验中均显示有一定抗肿瘤活性.Lapatinib对乳腺癌患者,尤其对曲妥株单抗耐药的局部晚期和转移性乳腺癌患者显示了较好疗效.以lapatinib为代表的TKI有望为乳腺癌的治疗开辟一条崭新的途径.
MoreAI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined